Incoming Democratic chairs of key committees have taken a step toward investigating MFN drug pricing agreements between drugmakers and the Trump administration. Local authorities and relevant stakeholders are closely monitoring the situation as fresh developments unfold on the ground. Officials noted that further verified updates and administrative measures will be shared following a detailed review.